Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald
August 8, 2018 6:58 AM EDTCantor Fitzgerald raised its price target on Arrowhead Research (NASDAQ: ARWR) to $18.00 (from $13.00) while maintaining a Overweight rating following 3Q18 financial and corporate updates.
Analyst Elemer Piros commented, "The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract... More
Arrowhead Research (ARWR) PT Raised to $17.50 at Chardan Capital Markets
August 8, 2018 6:55 AM EDTChardan Capital Markets raised its price target on Arrowhead Research (NASDAQ: ARWR) to $17.50 (from $16.00) while maintaining a Buy rating.
... MoreArrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
August 7, 2018 4:00 PM EDTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More